Methanesulfonyl Fluoride

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Methanesulfonyl Fluoride
Accession Number
DB13058
Type
Small Molecule
Groups
Investigational
Description

Methanesulfonyl Fluoride has been used in trials studying the treatment of Safety.

Structure
Thumb
Synonyms
Not Available
External IDs
SNX-001
Categories
UNII
9H250YYY0R
CAS number
558-25-8
Weight
Average: 98.09
Monoisotopic: 97.983778674
Chemical Formula
CH3FO2S
InChI Key
KNWQLFOXPQZGPX-UHFFFAOYSA-N
InChI
InChI=1S/CH3FO2S/c1-5(2,3)4/h1H3
IUPAC Name
methanesulfonyl fluoride
SMILES
CS(F)(=O)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Methanesulfonyl Fluoride.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Methanesulfonyl Fluoride.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Methanesulfonyl Fluoride.Experimental, Illicit
AcebutololMethanesulfonyl Fluoride may increase the bradycardic activities of Acebutolol.Approved, Investigational
AcetylcholineThe risk or severity of adverse effects can be increased when Methanesulfonyl Fluoride is combined with Acetylcholine.Approved
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Methanesulfonyl Fluoride.Approved
AlcuroniumThe therapeutic efficacy of Alcuronium can be decreased when used in combination with Methanesulfonyl Fluoride.Experimental
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Methanesulfonyl Fluoride.Experimental, Investigational
AlprenololMethanesulfonyl Fluoride may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Methanesulfonyl Fluoride.Approved
AmiodaroneMethanesulfonyl Fluoride may increase the bradycardic activities of Amiodarone.Approved, Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Methanesulfonyl Fluoride.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Methanesulfonyl Fluoride.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Methanesulfonyl Fluoride.Investigational
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
ArecolineThe risk or severity of adverse effects can be increased when Methanesulfonyl Fluoride is combined with Arecoline.Experimental
ArotinololMethanesulfonyl Fluoride may increase the bradycardic activities of Arotinolol.Investigational
AsenapineMethanesulfonyl Fluoride may increase the bradycardic activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Methanesulfonyl Fluoride.Investigational
AtenololMethanesulfonyl Fluoride may increase the bradycardic activities of Atenolol.Approved
AtracuriumThe therapeutic efficacy of Atracurium can be decreased when used in combination with Methanesulfonyl Fluoride.Approved, Experimental, Investigational
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Methanesulfonyl Fluoride.Approved, Vet Approved
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Methanesulfonyl Fluoride.Approved, Investigational
BefunololMethanesulfonyl Fluoride may increase the bradycardic activities of Befunolol.Experimental
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Methanesulfonyl Fluoride.Withdrawn
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Methanesulfonyl Fluoride.Approved, Vet Approved
BetaxololMethanesulfonyl Fluoride may increase the bradycardic activities of Betaxolol.Approved, Investigational
BethanecholThe risk or severity of adverse effects can be increased when Methanesulfonyl Fluoride is combined with Bethanechol.Approved
BevantololMethanesulfonyl Fluoride may increase the bradycardic activities of Bevantolol.Approved
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with Methanesulfonyl Fluoride.Approved, Investigational
BisoprololMethanesulfonyl Fluoride may increase the bradycardic activities of Bisoprolol.Approved
BopindololMethanesulfonyl Fluoride may increase the bradycardic activities of Bopindolol.Approved
BornaprineThe therapeutic efficacy of Bornaprine can be decreased when used in combination with Methanesulfonyl Fluoride.Experimental
BucindololMethanesulfonyl Fluoride may increase the bradycardic activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Methanesulfonyl Fluoride.Approved
BufuralolMethanesulfonyl Fluoride may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BupranololMethanesulfonyl Fluoride may increase the bradycardic activities of Bupranolol.Approved
ButylscopolamineThe therapeutic efficacy of Butylscopolamine can be decreased when used in combination with Methanesulfonyl Fluoride.Approved, Investigational, Vet Approved
CarbacholThe risk or severity of adverse effects can be increased when Methanesulfonyl Fluoride is combined with Carbachol.Approved
CarteololMethanesulfonyl Fluoride may increase the bradycardic activities of Carteolol.Approved
CarvedilolMethanesulfonyl Fluoride may increase the bradycardic activities of Carvedilol.Approved, Investigational
CeliprololMethanesulfonyl Fluoride may increase the bradycardic activities of Celiprolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Methanesulfonyl Fluoride is combined with Cevimeline.Approved
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Methanesulfonyl Fluoride.Withdrawn
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Methanesulfonyl Fluoride.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Methanesulfonyl Fluoride.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Methanesulfonyl Fluoride.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Methanesulfonyl Fluoride.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Methanesulfonyl Fluoride.Approved
CloranololMethanesulfonyl Fluoride may increase the bradycardic activities of Cloranolol.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Methanesulfonyl Fluoride.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Methanesulfonyl Fluoride.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Methanesulfonyl Fluoride.Approved, Investigational
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Methanesulfonyl Fluoride.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Methanesulfonyl Fluoride.Approved, Investigational
DesipramineMethanesulfonyl Fluoride may increase the bradycardic activities of Desipramine.Approved, Investigational
DesloratadineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Methanesulfonyl Fluoride.Approved, Investigational
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Methanesulfonyl Fluoride.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Methanesulfonyl Fluoride.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Methanesulfonyl Fluoride.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Methanesulfonyl Fluoride.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Methanesulfonyl Fluoride.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Methanesulfonyl Fluoride.Vet Approved
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Methanesulfonyl Fluoride.Withdrawn
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Methanesulfonyl Fluoride.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Methanesulfonyl Fluoride.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Methanesulfonyl Fluoride.Approved
DiphenhydramineThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Methanesulfonyl Fluoride.Approved, Investigational
DipyridamoleThe therapeutic efficacy of Methanesulfonyl Fluoride can be decreased when used in combination with Dipyridamole.Approved
EmeproniumThe therapeutic efficacy of Emepronium can be decreased when used in combination with Methanesulfonyl Fluoride.Experimental
EpanololMethanesulfonyl Fluoride may increase the bradycardic activities of Epanolol.Experimental
EpibatidineThe risk or severity of adverse effects can be increased when Methanesulfonyl Fluoride is combined with Epibatidine.Experimental
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Methanesulfonyl Fluoride.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Methanesulfonyl Fluoride.Approved
EsatenololMethanesulfonyl Fluoride may increase the bradycardic activities of Esatenolol.Experimental
EsmololMethanesulfonyl Fluoride may increase the bradycardic activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Methanesulfonyl Fluoride.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Methanesulfonyl Fluoride.Approved
EtanautineThe therapeutic efficacy of Etanautine can be decreased when used in combination with Methanesulfonyl Fluoride.Experimental
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
EtybenzatropineThe therapeutic efficacy of Etybenzatropine can be decreased when used in combination with Methanesulfonyl Fluoride.Experimental
FesoterodineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
FlavoxateThe therapeutic efficacy of Flavoxate can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Methanesulfonyl Fluoride.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Methanesulfonyl Fluoride.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Methanesulfonyl Fluoride.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Methanesulfonyl Fluoride.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Methanesulfonyl Fluoride.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Methanesulfonyl Fluoride.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Methanesulfonyl Fluoride.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Methanesulfonyl Fluoride.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Methanesulfonyl Fluoride.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Methanesulfonyl Fluoride.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Methanesulfonyl Fluoride.Approved
FluticasoneThe risk or severity of adverse effects can be increased when Fluticasone is combined with Methanesulfonyl Fluoride.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Methanesulfonyl Fluoride.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Methanesulfonyl Fluoride.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Methanesulfonyl Fluoride.Approved, Investigational, Withdrawn
GallamineThe therapeutic efficacy of Gallamine can be decreased when used in combination with Methanesulfonyl Fluoride.Experimental
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Methanesulfonyl Fluoride.Approved, Investigational, Vet Approved
GTS-21The risk or severity of adverse effects can be increased when Methanesulfonyl Fluoride is combined with GTS-21.Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Methanesulfonyl Fluoride.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Methanesulfonyl Fluoride.Investigational
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Methanesulfonyl Fluoride.Approved, Vet Approved
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
IndenololMethanesulfonyl Fluoride may increase the bradycardic activities of Indenolol.Withdrawn
Ipratropium bromideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Methanesulfonyl Fluoride.Investigational
LabetalolMethanesulfonyl Fluoride may increase the bradycardic activities of Labetalol.Approved
LandiololMethanesulfonyl Fluoride may increase the bradycardic activities of Landiolol.Investigational
LevobetaxololMethanesulfonyl Fluoride may increase the bradycardic activities of Levobetaxolol.Approved, Investigational
LevobunololMethanesulfonyl Fluoride may increase the bradycardic activities of Levobunolol.Approved
LobelineThe risk or severity of adverse effects can be increased when Methanesulfonyl Fluoride is combined with Lobeline.Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Methanesulfonyl Fluoride.Approved
MazaticolThe therapeutic efficacy of Mazaticol can be decreased when used in combination with Methanesulfonyl Fluoride.Experimental
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Methanesulfonyl Fluoride.Investigational
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Methanesulfonyl Fluoride.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Methanesulfonyl Fluoride.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Methanesulfonyl Fluoride.Vet Approved
MepindololMethanesulfonyl Fluoride may increase the bradycardic activities of Mepindolol.Experimental
MethacholineThe risk or severity of adverse effects can be increased when Methanesulfonyl Fluoride is combined with Methacholine.Approved, Investigational
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Methanesulfonyl Fluoride.Approved, Investigational
MethscopolamineThe therapeutic efficacy of Methscopolamine can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Methanesulfonyl Fluoride.Approved, Vet Approved
Methylscopolamine bromideThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
MetipranololMethanesulfonyl Fluoride may increase the bradycardic activities of Metipranolol.Approved
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
MetoprololMethanesulfonyl Fluoride may increase the bradycardic activities of Metoprolol.Approved, Investigational
MivacuriumMethanesulfonyl Fluoride may decrease the neuromuscular blocking activities of Mivacurium.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Methanesulfonyl Fluoride.Approved, Vet Approved
NadololMethanesulfonyl Fluoride may increase the bradycardic activities of Nadolol.Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Methanesulfonyl Fluoride.Investigational
NebivololMethanesulfonyl Fluoride may increase the bradycardic activities of Nebivolol.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Methanesulfonyl Fluoride is combined with Nicotine.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Methanesulfonyl Fluoride.Investigational
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with Methanesulfonyl Fluoride.Experimental, Investigational
OxitropiumThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
OxprenololMethanesulfonyl Fluoride may increase the bradycardic activities of Oxprenolol.Approved
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Methanesulfonyl Fluoride.Approved, Investigational
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Methanesulfonyl Fluoride.Approved
PenbutololMethanesulfonyl Fluoride may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
PhenglutarimideThe therapeutic efficacy of Phenglutarimide can be decreased when used in combination with Methanesulfonyl Fluoride.Experimental
PilocarpineThe risk or severity of adverse effects can be increased when Methanesulfonyl Fluoride is combined with Pilocarpine.Approved, Investigational
PindololMethanesulfonyl Fluoride may increase the bradycardic activities of Pindolol.Approved, Investigational
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
Platelet Activating FactorMethanesulfonyl Fluoride may increase the bradycardic activities of Platelet Activating Factor.Experimental
PractololMethanesulfonyl Fluoride may increase the bradycardic activities of Practolol.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Methanesulfonyl Fluoride.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Methanesulfonyl Fluoride.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Methanesulfonyl Fluoride.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Methanesulfonyl Fluoride.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Methanesulfonyl Fluoride.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Methanesulfonyl Fluoride.Approved, Experimental, Investigational
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
PropafenoneMethanesulfonyl Fluoride may increase the bradycardic activities of Propafenone.Approved
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
PropiverineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Methanesulfonyl Fluoride.Approved, Investigational
PropranololMethanesulfonyl Fluoride may increase the bradycardic activities of Propranolol.Approved, Investigational
QuinidineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Methanesulfonyl Fluoride.Approved, Investigational
RapacuroniumMethanesulfonyl Fluoride may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Methanesulfonyl Fluoride.Approved
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Methanesulfonyl Fluoride.Approved, Investigational
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
SotalolMethanesulfonyl Fluoride may increase the bradycardic activities of Sotalol.Approved
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Methanesulfonyl Fluoride.Approved
TalinololMethanesulfonyl Fluoride may increase the bradycardic activities of Talinolol.Investigational
TerbutalineMethanesulfonyl Fluoride may increase the bradycardic activities of Terbutaline.Approved
TertatololMethanesulfonyl Fluoride may increase the bradycardic activities of Tertatolol.Experimental
TimololMethanesulfonyl Fluoride may increase the bradycardic activities of Timolol.Approved
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Methanesulfonyl Fluoride.Approved, Withdrawn
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Methanesulfonyl Fluoride.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Methanesulfonyl Fluoride.Approved, Vet Approved
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Methanesulfonyl Fluoride.Approved, Investigational
TropatepineThe therapeutic efficacy of Tropatepine can be decreased when used in combination with Methanesulfonyl Fluoride.Experimental
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Methanesulfonyl Fluoride.Approved, Investigational
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Methanesulfonyl Fluoride.Approved
UmeclidiniumThe therapeutic efficacy of Umeclidinium can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
VareniclineThe risk or severity of adverse effects can be increased when Methanesulfonyl Fluoride is combined with Varenicline.Approved, Investigational
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Methanesulfonyl Fluoride.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
11207
PubChem Substance
347829186
ChemSpider
10734

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentSafety1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility5.16 mg/mLALOGPS
logP0.5ALOGPS
logP-0.48ChemAxon
logS-1.3ALOGPS
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area34.14 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity15.47 m3·mol-1ChemAxon
Polarizability6.95 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as sulfonyl fluorides. These are compounds containing a sulfonyl (R-S(=O)2-R') functional group singly bonded to a fluorine atom.
Kingdom
Organic compounds
Super Class
Organohalogen compounds
Class
Sulfonyl halides
Sub Class
Sulfonyl fluorides
Direct Parent
Sulfonyl fluorides
Alternative Parents
Sulfonyls / Organosulfonic acids and derivatives / Organic oxides / Hydrocarbon derivatives
Substituents
Sulfonyl / Sulfonyl fluoride / Organosulfonic acid or derivatives / Organic sulfonic acid or derivatives / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organosulfur compound / Aliphatic acyclic compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 20:30 / Updated on June 02, 2018 08:45